Therapy

Psychiatry Drugs Foster Care Children – Elnita

I took my video camera to a Foster Care Alumni meeting and asked seven foster kids to tell me about there experiences in Child Protective Services while wards of the state.

One thing they all had in common was massive over drugging with psychiatric drugs.

Child placement agencies, foster parents, RTCs (Residential Treatment Centers) and Therapeutic Foster Homes get paid a certain amount of money each day for taking care of a foster child. The amount of money they get paid depends on a level of care system. The more difficult the child or the more problems that child has, the more money you get.

A child at the basic level of care is worth about 17 dollars a day where as a child in the highest level of care could be worth as much as a 1000 dollars a day. This puts the incentive on diagnosing children with behavior problems to justify raising their level of care. A child on psychiatric drugs is worth more than a child without problems.

It is not uncommon for a foster child to be placed on many different psychotropic drugs at the same time. Some investigations have found children on as many as 13 mind altering drugs prescribed by a psychiatrists at one time.

These drugs include all categories of psychiatric drugs; antidepressants, antipsychotics, mood stabilizers, anxiety medications, anticonvulsants medications, etc.

The SSRI drugs are commons such as Paxil, Zoloft, Prozac, etc. Also a number of these children described taking Risperdal, Zyprexa, Geodon and other new generation antipsychotics which have been linked to weight gain, obesity and diabetes.

Visit the website for the Foster Care Alumni of America.

http://www.fostercarealumni.org/

This video was produced by psychetruth.

http://www.youtube.com/psychetruth
http://www.myspace.com/psychtruth
http://www.livevideo.com/psychetruth

The video may be copied, publicly displayed or used for any strictly non-commercial use provided it remain in it’s full unedited form. Alteration or commercial use is strictly prohibited.

Copyright 2007 Zoe Sofia.

Duration : 0:9:2

Read the rest of this entry »

Psychiatry Drugs Foster Care Children – Tristen

I took my video camera to a Foster Care Alumni meeting and asked seven foster kids to tell me about there experiences in Child Protective Services while wards of the state.

One thing they all had in common was massive over drugging with psychiatric drugs.

Child placement agencies, foster parents, RTCs (Residential Treatment Centers) and Therapeutic Foster Homes get paid a certain amount of money each day for taking care of a foster child. The amount of money they get paid depends on a level of care system. The more difficult the child or the more problems that child has, the more money you get.

A child at the basic level of care is worth about 17 dollars a day where as a child in the highest level of care could be worth as much as a 1000 dollars a day. This puts the incentive on diagnosing children with behavior problems to justify raising their level of care. A child on psychiatric drugs is worth more than a child without problems.

It is not uncommon for a foster child to be placed on many different psychotropic drugs at the same time. Some investigations have found children on as many as 13 mind altering drugs prescribed by a psychiatrists at one time.

These drugs include all categories of psychiatric drugs; antidepressants, antipsychotics, mood stabilizers, anxiety medications, anticonvulsants medications, etc.

The SSRI drugs are commons such as Paxil, Zoloft, Prozac, etc. Also a number of these children described taking Risperdal, Zyprexa, Geodon and other new generation antipsychotics which have been linked to weight gain, obesity and diabetes.

Visit the website for the Foster Care Alumni of America.

http://www.fostercarealumni.org/

This video was produced by psychetruth.

http://www.youtube.com/psychetruth
http://www.myspace.com/psychtruth
http://www.livevideo.com/psychetruth

The video may be copied, publicly displayed or used for any strictly non-commercial use provided it remain in it’s full unedited form. Alteration or commercial use is strictly prohibited.

Copyright 2007 Zoe Sofia.

Duration : 0:9:58

Read the rest of this entry »

Magnetic-materials specialist Kevin O’Grady predicts a big future for magnetic nanoparticles in clinical applications ranging from targeted drug delivery to the heat treatment of cancerous tumours.

Kevin O’Grady, professor of physics at the University of York, UK, provides an accessible overview that unpicks the fundamental science of magnetic nanoparticles as well as looking ahead to the delivery of real-world diagnostic and therapeutic nanoparticle technologies for clinical medicine.

Duration : 0:8:8

Read the rest of this entry »

Wyeth is cautioning healthcare professionals about therapeutic drug monitoring for Rapamune (sirolimus). Rapamune is used to prevent organ rejection in certain renal transplant patients.

The company points out that Rapamune blood concentrations can be assayed using either chromatographic or immunoassay tests, and that the results of these two methodologies are not interchangeable. If the assay method were switched during a patient’s treatment with Rapamune, the dose of the drug might be adjusted improperly – too low a dose could lead to allograft rejection, and too high a dose could expose the patient to toxic side effects.

Wyeth is advising clinicians who manage patients on Rapamune to determine which assay is used in their laboratory, if there has been any change in the assay or in the laboratory’s reference range, and if the institution or referring center has changed its recommended range. The bottom line is that it is critical for clinicians to communicate with their laboratories about any changes in the assays used to measure blood concentrations in Rapamune patients.

FDA Patient Safety News: April 2010

For more information, please see our website:
http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/psn/transcript.cfm?show=97#6

Duration : 0:1:16

Read the rest of this entry »

The Jesus Christ Security Foundation was formed to fight the menace and effects of social exclusion. The purpose of the Foundation is, among others, the re-socialization of homeless individuals who have addictions not only to psychoactive drugs, but also to behaviors and people.

The method used by the Foundation is comprehensive in character. The entire process of re-adaptation consists of successive steps such as: motivation for treatment and healing, counselling and therapeutic interaction as well as on-going assistance and strengthening of those re-socialization effects that have been achieved.

Separate institutions which form The Jesus Christ Security Foundation are called upon to realize these goals. They may be considered as elements of the Foundations counseling system. The Foundation bases its work on the voluntary payment of room and board. The Foundation already has several branches in Poland; in Boguszowie- Gorcach, Cieszynie, Krotoszynie, Jarocinie, Kamiennej Górze, Świebodzicach, Wałbrzychu, Stargardzie Szczecińskim, Strzelinie and Wierzchowicach. The Foundation works together with local town and city councils to realize the goal of co-operation and action against social exclusion. We want to create respectable and dignified conditions for those under our care in which they may be able to obtain not just physical help but first and foremost psychological and therapeutic help.

We want to provide help to those in need. We do not want to passively watch the progressive impoverishment and degeneration of our local society. We want to create a real home for those under our care so that they may know they are needed in society and that they can function normally in it. Todays reality is that almost every Polish family is touched by addiction, co-dependency, unemployment and even homelessness.

The people under our care are individuals with various kinds of problems and do not have any income. Because of this we try to find resources to support them. We ask for help which can allow us to broaden our ministry and at the same time limit the progressive impoverishment of that part of society touched by unemployment and the inability to adjust in society. On behalf of those in our care and in the name of our Foundation we are extremely thankful for all help we receive.

Marian Rogowski – Founder

CONTACT: Jesus Christ Security Foundation (Fundacja Jesus Christ Security)
ul. Kołłątaja 6; 58-370 Boguszów Gorce POLAND
E-mail: marro725@wp.pl ; Tel. 4874 8449325; cell phone: 48519179438

Duration : 0:16:57

Read the rest of this entry »

GlaxoSmithKline is alerting healthcare professionals about the dangers of reconstituting Relenza (zanamivir) Inhalation Powder into a liquid and using it in a nebulizer or mechanical ventilator. The powder, which is used in the treatment and prophylaxis of influenza, is only intended to be inhaled using a Diskhaler.

In a recent letter, the company notes that some practitioners have dissolved Relenza Inhalation Powder in various solutions. Using a mechanical ventilator, they then delivered the drug in nebulized form to patients who could not take oral influenza medications or could not inhale the drug using a Diskhaler.

The letter describes the death of a pregnant woman with influenza who was treated with Relenza Inhalation Powder that had been solubilized and administered by mechanical ventilation. The patient’s death was attributed to obstruction of the ventilator, possibly from stickiness caused by lactose in the Relenza Inhalation Powder.

The letter reminds practitioners that the safety, effectiveness and stability of Relenza Inhalation Powder have not been established for nebulization, that this use has not been approved by the FDA, and that this drug should only be administered using the Diskhaler device that comes with it.

FDA Patient Safety News: January 2010

For more information, please see our website:
http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/psn/transcript.cfm?show=94#3

Duration : 0:1:24

Read the rest of this entry »

Lysergic acid diethylamide, abbreviated LSD or LSD-25, also known as lysergide and colloquially as acid, is a semisynthetic psychedelic drug of the ergoline and tryptamine families. LSD is non-addictive, non-toxic, and is well known for its psychological effects which can include altered thinking processes, closed and open eye visuals, synaesthesia, a sense of time distortion, ego death and spiritual experiences, as well as for its key role in 1960s counterculture. It is used mainly by psychonauts as an entheogen, recreational drug and as an agent in psychedelic therapy.

LSD was first synthesized by Albert Hofmann in 1938 from ergot, a grain fungus that typically grows on rye. The short form LSD comes from its early code name LSD-25, which is an abbreviation for the German “Lysergsäure-diethylamid” followed by a sequential number. LSD is sensitive to oxygen, ultraviolet light, and chlorine, especially in solution, though its potency may last for years if it is stored away from light and moisture at low temperature. In pure form it is a colorless, odorless, and mildly bitter solid. LSD is typically delivered orally, usually on a substrate such as absorbent blotter paper, a sugar cube, or gelatin. In its liquid form, it can also be administered by intramuscular or intravenous injection. LSD is very potent, with 2030 µg (micrograms) being the threshold dose.

Introduced by Sandoz Laboratories, with trade-name Delysid, as a drug with various psychiatric uses in 1947, LSD quickly became a therapeutic agent that appeared to show great promise. However, the emerging recreational use of the drug by youth culture in the Western world during the 1960s led to a political firestorm that resulted in its prohibition. A number of organizations—including the Beckley Foundation, MAPS, Heffter Research Institute and the Albert Hofmann Foundation—exist to fund, encourage and coordinate research into its medicinal uses.

LSD was first synthesized on November 16, 1938 by Swiss chemist Dr. Albert Hofmann at the Sandoz Laboratories in Basel, Switzerland as part of a large research program searching for medically useful ergot alkaloid derivatives. LSD’s psychedelic properties were discovered 5 years later when Hofmann accidentally ingested an unknown quantity of the chemical. The first intentional ingestion of LSD occurred on April 19, 1943, when Dr. Hofmann ingested 250 µg of LSD. He hypothesized this would be a threshold dose based on the dosages of other ergot alkaloids. Hofmann found the effects to be much stronger than he anticipated. Sandoz Laboratories introduced LSD as a psychiatric drug in 1947.

Beginning in the 1950s the US Central Intelligence Agency began a research program code named Project MKULTRA. Experiments included administering LSD to CIA employees, military personnel, doctors, other government agents, prostitutes, mentally ill patients, and members of the general public in order to study their reactions, usually without the subject’s knowledge. The project was revealed in the US congressional Rockefeller Commission report in 1975.

In 1963 the Sandoz patents expired on LSD. Also in 1963, the US Food and Drug Administration classified LSD as an Investigational New Drug, which meant new restrictions on medical and scientific use. Several figures, including Aldous Huxley, Timothy Leary, and Al Hubbard, began to advocate the use of LSD. LSD became central to the counterculture of the 1960s. On October 24, 1968, possession of LSD was made illegal in the United States. The last FDA approved human study with LSD, for use in dying cancer patients, ended in 1980. Legally approved and regulated psychiatric use of LSD continued in Switzerland until 1993. Today, medical research is resuming around the world.

Duration : 0:9:59

Read the rest of this entry »

These women have completed a rigorous therapeutic community modified treatment milieu. Their successful graduation from our program proves to the court that they can live a healthy lifestyle and be good parents to their children. We are so proud of all of our graduates – they are the best examples of why treatment works.

Duration : 0:2:25

Read the rest of this entry »

American Regent has issued new precautionary measures for preventing anaphylactic-type reactions when administering Dexferrum (iron dextran injection).

An updated boxed warning for Dexferrum now says that a test dose should be administered before giving the first therapeutic dose. A test dose of 0.5 mL should be given gradually, over at least five minutes. Although reactions are usually seen within a few minutes, patients should be observed for at least an hour after the test dose.

The boxed warning also points out that some patients have experienced fatal reactions after receiving the test dose. Others have died after tolerating the test dose and then receiving a therapeutic dose. Because of this, patients should be observed for signs and symptoms of anaphylactic-type reactions every time Dexferrum is administered, and resuscitation equipment and trained personnel should be readily available.

The company’s letter says that patients with a history of drug allergy or multiple drug allergies, and patients receiving ACE inhibitors, may have a higher risk of anaphylactic-type reactions. It also reminds clinicians that Dexferrum should only be used for patients whose iron deficiency isn’t amenable to oral iron therapy.

FDA Patient Safety News: January 2010

For more information, please see our website:
http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/psn/transcript.cfm?show=94#6

Duration : 0:1:28

Read the rest of this entry »

Excerpts from “The Mind – Benders: Lysergic acid diethylamide (LSD) and the Hallucinogens”. This film explores the history of hallucinogenic drugs, and specifically the effects of lysergic acid diethylamide (LSD). Combining graphics that suggest a hallucinogenic experience, snippets of interviews with users (who explain their reasons for taking the drug) and doctors, and taped sessions of research with volunteers, the film delves into the destructive uses of the drug. Producer: National Archives and Records Administration. Creative Commons license: Public Domain

Chemist Albert Hofmann, working at the Sandoz Corporation pharmaceutical laboratory in Switzerland, first synthesized LSD in 1938. He was conducting research on possible medical applications of various lysergic acid compounds derived from ergot, a fungus that develops on rye grass. Searching for compounds with therapeutic value, Hofmann created more than two dozen ergot-derived synthetic molecules.

LSD is sold on the street in tablets, capsules, and occasionally in liquid form. It is an odorless and colorless substance with a slightly bitter taste that is usually ingested orally. It is often added to absorbent paper, such as blotter paper, and divided into small decorated squares, with each square representing one dose.

CONTROL STATUS

LSD is a Schedule I substance under the Controlled Substances Act. Schedule I drugs, which include heroin and MDMA, have a high potential for abuse and serve no legitimate medical purpose. Its two precursors lysergic acid and lysergic acid amide are both in Schedule III of the CSA. The LSD precursors ergotamine and ergonovine are List I chemicals.

STREET TERMS

Acid, blotter acid, window pane, dots, mellow yellow

SHORT-TERM EFFECTS

The short-term effects of LSD are unpredictable. They depend on the amount of the drug taken; the user’s personality, mood, and expectations; and the surroundings in which the drug is used. Usually, the user feels the first effects of the drug within 30 to 90 minutes of ingestion. These experiences last for extended periods of time and typically begin to clear after about 12 hours. The physical effects include dilated pupils, higher body temperature, increased heart rate and blood pressure, sweating, loss of appetite, sleeplessness, dry mouth, and tremors. Sensations may seem to “cross over” for the user, giving the feeling of hearing colors and seeing sounds. If taken in a large enough dose, the drug produces delusions and visual hallucinations.

LONG-TERM EFFECTS

LSD users often have flashbacks, during which certain aspects of their LSD experience recur even though they have stopped taking the drug. In addition, LSD users may develop long-lasting psychoses, such as schizophrenia or severe depression. LSD is not considered an addictive drug – that is, it does not produce compulsive drug-seeking behavior as cocaine, heroin, and methamphetamine do. However, LSD users may develop tolerance to the drug, meaning that they must consume progressively larger doses of the drug in order to continue to experience the hallucinogenic effects that they seek.

TRAFFICKING TRENDS

LSD trafficking and abuse have decreased sharply since 2000, and a resurgence does not appear likely in the near term. National-level data regarding LSD availability (such as LSD seizures and LSD-related arrests) show a sharp decrease since 2000. LSD seizures, for example, decreased 100 percent from 2000 through 2005, and LSD-related arrests decreased 84.9 percent from 2000 through 2004 (see 2006 National Drug Threat Assessment Appendix B, Table 4 and Table 5). Demand for LSD also has decreased sharply since 2000, as reflected in national-level prevalence studies. In fact, Monitoring the Future (MTF) and National Survey on Drug Use and Health (NSDUH) data show that rates of past year use for LSD have decreased significantly for nearly every sampled age group (see 2006 National Drug Threat Assessment Appendix B, Table 1 and Table 2). Production of the drug also appears to be limited–with no reported laboratory seizures in 2004–and controlled by a relatively small number of experienced chemists. Moreover, LSD distribution appears to be very limited in most areas of the country. As such, resurgence in widespread LSD distribution is unlikely in the near term.

USE/USER POPULATION

LSD is abused by teenagers and young adults in connection with raves, nightclubs and concert settings.

Approximately 1.9% of eighth graders, 2.5% of tenth graders, and 3.5% of twelfth graders surveyed as part of the 2005 Monitoring the Future study reported lifetime use of LSD. Approximately 44% of eighth graders, 60.8% of tenth graders, and 69.9% of twelfth graders surveyed in 2005 reported that taking LSD regularly was a “great risk.” Additional survey results indicate that 5.6% of college students and 13.4% of young adults reported lifetime use of LSD.

Duration : 0:18:17

Read the rest of this entry »